Patients suffering from TD1 (patient number projected at 63-94 million in 2045) and patients TD2 (insulin requiring patients 10-20% of the total population, number projected at more than 500 million by 2045).
T1D patients require exogenous insulin, resulting in an exorbitant number of actions: 100.000-500.000 in one patient’s life. BIP will free T1D subjects from therapeutic actions and from related psychological burden. BIP invisibility will make the system particularly appealing also for adolescents, thus maximizing its psychological acceptance. The patented technology, in the future, may be used for chronic and temporized delivery of testosterone, progesterone or estrogens in patients affected by hypothyroidism, as well as for an on-demand intrathecal delivery of analgesics in patients affected by chronic pain.
Type 1 diabetes is a pandemic chronic disease affecting patient’s quality of life, increasing morbidity and mortality and severely weighting on the national healthcare expenses. BIP addresses this urgent need by developing a radically new biomedical technology that will restore physiologic glycemic control. The new technology will allow to drastically reduce the excess costs related to microvascular complications and hospitalization costs for severe hypoglycemia.
Who is supporting us
Do you want to receive news and updates on the project?
Fill out the form to receive news about the project